Join Professor Peter Nash from the Griffith University in Brisbane, as well as Professors Andrew Cope, Professor of Rheumatology and Head of the Centre for Rheumatic Diseases at Kings College London, Professor Paul Emery, Clinical Professor and Director of the Leeds Biomedical Research Centre, and Professor John Isaacs, Professor of clinical immunology and Director of Newcastle Biomedicine Versus Arthritis Experimental Arthritis Treatment Centre.

Together they discuss the recent paper ‘Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial’, published in The Lancet on 13th February 2024.